HOTH News and Press, Hoth Therapeutics Inc. From 03/20/24

2024-03-20 06:35:00 ET 3 Rules for New Penny Stocks Investors to Follow Investing in penny stocks presents a unique opportunity for investors looking to diversify their portfolios with high-potential, low-cost options. The allure of buying penny stocks lies in their affordability, o...

2024-03-19 10:32:46 ET More on Hoth Therapeutics Hoth stock jumps on FDA approval of study expansion for HT-001 Seeking Alpha’s Quant Rating on Hoth Therapeutics Historical earnings data for Hoth Therapeutics Financial information for Hoth Therapeutics...

2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

A look at the top 10 most actives in the United States Ontrak Inc. (OTRK) rose 214.5% to $0.5975 on volume of 79,666,583 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.0% to $3.7703 on volume of 36,416,698 shares Enveric Biosciences Inc. (ENVB) rose 35.5% to $1.49 on vol...

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ PR Newswire HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease. ...

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio PR Newswire NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company , today announced that it will continue its ...

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic PR Newswire Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK , Feb....

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 PR Newswire NEW YORK , Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Of...

2024-01-18 09:57:45 ET More on Hoth Therapeutics Hoth stock jumps on positive FDA feedback on drug HT-KIT Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy Seeking Alpha’s Quant Rating on Hoth Therapeutics Historical...

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients PR Newswire Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics NEW YORK , Jan. 18, 2024 ...